Daily Cardiology Research Analysis
Analyzed 113 papers and selected 3 impactful papers.
Summary
Three impactful studies highlight precision cardiology advances: exercise phenotyping in HFpEF revealed five distinct pathophysiologic clusters with differing prognoses; a dynamic biomarker (peri-procedural change in renalase) independently predicted CMR-defined microvascular obstruction after primary PCI; and a large real-world registry showed fluoroscopy-only guidance for LAAO achieved comparable long-term stroke prevention to echo-guided procedures. Together they support personalized risk stratification, biomarker-guided care, and resource-efficient procedural strategies.
Research Themes
- Precision phenotyping and risk stratification in HFpEF
- Periprocedural biomarkers predicting reperfusion injury (microvascular obstruction)
- Streamlined imaging strategies for structural heart interventions
Selected Articles
1. Distinct Exercise Response Patterns in Patients With Heart Failure With Preserved Ejection Fraction.
Using combined CPET and stress echocardiography with unsupervised clustering, the authors identified five reproducible HFpEF exercise phenotypes with distinct pathophysiology and significantly different outcome risks. Phenotypes characterized by impaired peripheral oxygen extraction, reduced LV systolic reserve, or chronotropic incompetence showed worse composite outcomes.
Impact: This work advances precision phenotyping in HFpEF, moving beyond resting measures to exercise physiology to stratify risk and potentially tailor therapy.
Clinical Implications: Exercise phenotyping can guide targeted interventions (e.g., addressing chronotropic incompetence or peripheral extraction deficits) and enrich clinical trials by selecting high-risk phenotypes.
Key Findings
- Unsupervised clustering of 61 CPET-stress echocardiography variables identified five HFpEF exercise phenotypes.
- Phenotypes 2 (impaired peripheral oxygen extraction), 4 (reduced LV systolic reserve), and 5 (chronotropic incompetence) had higher risk of all-cause death/unplanned CV hospitalization vs phenotype 1 (HR 1.76, 2.15, and 2.19).
- All five phenotypes were replicated in an independent validation cohort.
Methodological Strengths
- Multicenter cohort with derivation and validation sets
- Unsupervised, graph-based clustering integrating CPET and stress echocardiography with outcome validation
Limitations
- Observational design limits causal inference and potential residual confounding
- Generalizability may be constrained to tertiary centers; interventional validation is needed
Future Directions: Prospective interventional trials targeting phenotype-specific mechanisms (e.g., rate-adaptive pacing for chronotropic incompetence) and external validation across broader care settings.
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disease characterized by exercise intolerance. Defining pathophysiologically distinct subgroups allows more personalized therapy, but efforts mainly relied on resting examinations. This study aimed to define HFpEF phenotypes based on exercise limitations using combined cardiopulmonary exercise testing with stress echocardiography. METHODS: A total of 913 patients with HFpEF were recruited from 4 third-line centers and divided into derivation (n=623) and validation cohorts (n=290). Unsupervised graph-based clustering of 61 cardiopulmonary exercise testing with stress echocardiography variables was used to identify HFpEF exercise phenotypes. Pathophysiological characteristics, exercise capacity, and clinical outcomes were compared between phenotypes. RESULTS: In the derivation cohort, cluster analysis identified 5 distinct HFpEF exercise phenotypes characterized by specific exercise responses: mild diastolic dysfunction (phenotype 1), impaired peripheral oxygen extraction (phenotype 2), right ventricular-pulmonary artery uncoupling (phenotype 3), reduced left ventricular systolic reserve (phenotype 4), and chronotropic incompetence (phenotype 5). The composite outcome of all-cause death and unplanned cardiovascular hospitalization differed significantly across phenotypes, with phenotypes 2 (hazard ratio [HR], 1.76 [95% CI, 1.07-2.91]), 4 (HR, 2.15 [95% CI, 1.27-3.65]), and 5 (HR, 2.19 [95% CI, 1.33-3.61]) showing higher rates of the primary combined outcome compared with phenotype 1. All phenotypes were replicated in the validation cohort. CONCLUSIONS: Deep phenotyping of the exercise response in patients with HFpEF revealed 5 distinct phenogroups with marked differences in pathophysiology, exercise performance, and clinical outcomes. This subclassification may support more personalized therapeutic strategies and improve risk stratification in HFpEF.
2. Periprocedural 24-Hour Change in Renalase Adds Incremental Value for Early Risk Stratification of Cardiovascular Magnetic Resonance-Defined Microvascular Obstruction in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Prospective Cohort Study.
In a prospective STEMI cohort undergoing primary PCI, the 24-hour peri-procedural change in renalase independently associated with CMR-defined microvascular obstruction and improved early risk stratification beyond clinical factors. This supports Δ-renalase as a rapid biomarker aligned with the temporal evolution of reperfusion injury.
Impact: Introduces a dynamic, easily measurable biomarker tied to reperfusion biology that can anticipate microvascular obstruction, a key determinant of infarct healing and outcomes.
Clinical Implications: Δ-renalase measured within 24 hours post-PCI could help identify patients at risk for MVO who may benefit from intensified cardioprotection or tailored follow-up and imaging.
Key Findings
- Among 266 STEMI patients, CMR-defined MVO occurred in 44.4% and was independently associated with the 24-hour periprocedural change in renalase.
- Δ-renalase improved early risk stratification for MVO beyond clinical variables.
- The biomarker’s temporal rise paralleled reperfusion injury maturation, enabling practical 24-hour post-PCI measurement.
Methodological Strengths
- Prospective cohort with standardized timing of biomarker sampling and CMR assessment
- Use of gold-standard CMR to define microvascular obstruction
Limitations
- Single-center design may limit generalizability; external validation is needed
- Short follow-up (90 days) and potential unmeasured confounding around reperfusion care
Future Directions: Multicenter external validation, integration into multimarker or imaging-clinical models, and interventional trials testing biomarker-guided adjunctive therapies.
BACKGROUND: Renalase, a stress-responsive enzyme with cardioprotective effects, exhibits a postreperfusion surge that temporally parallels the maturation of microvascular obstruction (MVO). We investigated whether the periprocedural change in renalase (Δ-renalase) is independently associated with MVO after primary percutaneous coronary intervention (PPCI). METHODS: This prospective cohort study enrolled 266 consecutive patients with ST-segment-elevation myocardial infarction within 12 hours of symptom onset undergoing PPCI at the Third Xiangya Hospital (August 2024 to July 2025). Serum renalase was measured before and 24 hours after PPCI. Cardiovascular magnetic resonance performed 2 to 5 days after PPCI was used to define MVO. All enrolled patients were followed for 90 days after hospital discharge. RESULTS: The cohort had a mean age of 60.1 years, and 31.6% were women. MVO was identified in 118 patients (44.4%). In univariable analysis, Δ-renalase showed a significant overall association with MVO ( CONCLUSIONS: In patients with ST-segment-elevation myocardial infarction treated with PPCI, periprocedural Δ-renalase is independently associated with cardiovascular magnetic resonance-defined MVO and improves risk stratification, supporting its potential for early risk prediction. REGISTRATION: URL: https://www.clinical.trials.gov; Unique Identifier: NCT06669520.
3. Effect of Fluoroscopy-Only Versus Transesophageal Echocardiography/Intracardiac Echocardiography Guidance in Left Atrial Appendage Occlusion on Stroke Prevention: Analysis From the RECORD I Study.
In 3096 real-world LAAO procedures, fluoroscopy-only guidance achieved comparable 3-year composite outcomes (death, stroke, systemic embolism) to TEE/ICE-guided procedures after IPTW and propensity matching. Periprocedural complications were low in both groups, supporting fluoroscopy-only as a streamlined option in experienced centers using WATCHMAN 2.5.
Impact: Addresses a practical, scalable question linking procedural imaging strategy to long-term efficacy in stroke prevention, with implications for access and resource utilization.
Clinical Implications: In selected patients and experienced centers, fluoroscopy-only LAAO may reduce reliance on TEE/ICE, anesthesia, and resource use without compromising long-term stroke prevention.
Key Findings
- Among 3096 LAAO cases, 84.1% were echo-guided and 15.9% fluoroscopy-only; adjusted analyses showed comparable 3-year composite outcomes.
- Periprocedural complications before discharge were low in both groups (1.4% echo vs 0.6% fluoro-only; adjusted absolute difference -0.67%).
- Findings pertain to first-generation WATCHMAN 2.5 and experienced centers; approach may enhance accessibility.
Methodological Strengths
- Large, prospective multicenter registry with 3-year follow-up
- Robust confounding control using IPTW and 1:1 propensity score matching
Limitations
- Nonrandomized design; potential residual confounding and selection bias
- Generalizability limited to WATCHMAN 2.5 and experienced centers
Future Directions: Randomized or pragmatic trials comparing imaging strategies, evaluation with newer device generations, and assessment of anesthesia/resource utilization and patient-centered outcomes.
BACKGROUND: Evidence regarding the link between imaging modality and stroke prevention outcomes of left atrial appendage occlusion is currently lacking. METHODS: The RECORD (Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial Appendage Closure Technology) trial prospectively enrolled 3096 consecutive patients undergoing left atrial appendage occlusion from 39 Chinese centers between April 1, 2019, and October 31, 2020. In the current analyses, patients were stratified into the echocardiographic guidance (transesophageal echocardiography/intracardiac echocardiography) group and the fluoroscopy-only group. The primary end point was the composite end point of death, stroke, or systemic embolism at 3 years. Outcomes were estimated using the Kaplan-Meier method. Inverse probability of treatment weighting and 1:1 propensity score matching were performed to calculate hazard ratios (HRs) for each outcome at the time of interest. RESULTS: Among 3096 participants, 2603 (84.1%) underwent transesophageal echocardiography/intracardiac echocardiography-guided procedures and 493 (15.9%) underwent fluoroscopy-only guided procedures. Before discharge, procedural complications occurred in 34 patients (1.4%) in the transesophageal echocardiography/intracardiac echocardiography group and 3 patients (0.6%) in the fluoroscopy-only group (inverse probability of treatment weighting-adjusted absolute difference, -0.67 [95% CI, -1.39 to 0.05], CONCLUSIONS: Fluoroscopy-only guidance, without compromising long-term stroke prevention efficacy, may serve as a streamlined and potentially accessible alternative for left atrial appendage occlusion procedures performed with the first-generation WATCHMAN 2.5 device, and these findings apply to select patients and experienced centers. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT03917563.